Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

New South Wales. Sydney, Australia Clinical Trials

A listing of New South Wales. Sydney, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (60) clinical trials

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To demonstrate safety and feasibility of ipilimumab and nivolumab at the standard doses of drug in solid tumor and relapsed refractory HIV-classical Hodgkin lymphoma (cHL) participants with human immunodeficiency virus (HIV) infection given the possibility of increased toxicity based on immune activation, co-morbidity, or interference with highly …

Phase

0.0 miles

Learn More »

Study of Safety Pharmacokinetics and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

This is a first-in-human, Phase 1a/1b (dose escalation and expansion) study of BGB-3245 in participants with tumors harboring B-RAF mutations that are likely to respond to a RAF dimer inhibitor. BGB-3245 is a second-generation B-RAF inhibitor that has demonstrated potent inhibitory activity against the RAF family of serine/threonine kinases preclinically. …

Phase

0.0 miles

Learn More »

Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Objective: Designing clinical trials for advanced retinal disease represents an especially difficult challenge due to the lack of suitable outcome measures. Clinical measures such as visual field and area of atrophy measured with multimodal imaging may be highly variable and/or difficult to measure in this population. A main contributor to …

Phase

0.0 miles

Learn More »

A Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1

This study will be conducted in two stages and will test the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in HIV-1 infected participants undergoing ART interruption.

Phase

0.0 miles

Learn More »

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

This phase 1, open label, multicentre, dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lu-PSMA in patients with mCRPC. Patients with mCRPC who have previously progressed on a novel AR targeted agent (abiraterone and/or enzalutamide and/or apalutamide) and have not had …

Phase

0.0 miles

Learn More »

CLN-0046: Treatment of AMD Subjects With OTX-TKI

A multi-center, dose escalation, Phase 1, safety, tolerability and efficacy study to evaluate three dose groups of the OTX-TKI implant to treat subjects with a diagnosis of primary subfoveal neovascularization secondary to AMD.

Phase

0.0 miles

Learn More »

A Study of Itolizumab (EQ001) to Evaluate the Safety Tolerability PK PD and Clinical Activity in Uncontrolled Asthma

The study will enroll up to 40 subjects, with up to 5 dose escalating cohorts of 8 patients enrolled in a 3:1 ratio. Subjects will receive either itolizumab or placebo administered subcutaneously every two weeks (over 8 weeks) for a total of 5 doses with 4 weeks of follow-up.

Phase

0.0 miles

Learn More »

A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off Rhegmatogenous Retinal Detachment

The purpose of this study is to evaluate the safety and tolerability of ONL1204 in participants with Macula-off, Rhegmatogenous Retinal Detachment (RRD). RRD is an acute and serious vision threatening condition in which a tear in the retina, typically resulting from a vitreous detachment, allows liquid to accumulate under the …

Phase

0.18 miles

Learn More »

Study of the Safety Pharmacokinetics and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK105 as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase …

Phase

0.9 miles

Learn More »